Sign in Subscribe
Cancer research

Obesity and Diabetes Exacerbate Cardiovascular Risks in Cancer Patients

Strategic Insights

— 1 min read

A new study published in the Journal of the American Heart Association has found that body mass index (BMI) and glycemic status significantly affect cardiovascular risks in cancer patients undergoing anthracycline-based chemotherapy. The research, led by Iokfai Cheang and colleagues from Jiangsu Province Hospital, analyzed data from 11,393 chemotherapy-naive patients who initiated anthracycline-based chemotherapy between 2000 and 2019. The study concluded that patients with concurrent obesity and diabetes/prediabetes are at the highest risk of major adverse cardiovascular events (MACE).

Key Takeaways:

  • The study analyzed data from 11,393 chemotherapy-naive patients who initiated anthracycline-based chemotherapy between 2000 and 2019.
  • The research found that body mass index (BMI) and glycemic status significantly affect cardiovascular risks in cancer patients undergoing anthracycline-based chemotherapy.
  • Patients with concurrent obesity and diabetes/prediabetes are at the highest risk of major adverse cardiovascular events (MACE).
  • The study emphasizes the need for tailored risk assessment and management in cancer patients undergoing anthracycline-based chemotherapy.
  • Iokfai Cheang and colleagues from Jiangsu Province Hospital led the research and published the findings in the Journal of the American Heart Association.
  • The study highlights the importance of considering BMI and glycemic status when assessing cardiovascular risks in cancer patients.

Statistics:

  • 11,393 chemotherapy-naive patients were included in the study.
  • The study analyzed data from patients who initiated anthracycline-based chemotherapy between 2000 and 2019.
  • 14.1% of patients had concurrent obesity and diabetes/prediabetes.
  • The risk of MACE was significantly higher in patients with concurrent obesity and diabetes/prediabetes compared to those without.
  • The study found that for every 10% increase in excess body weight, the risk of MACE increased by 16%.

Sources:

  • Interaction of Body Mass Index and Glycemic Status on Cardiovascular Outcomes in Patients With Cancer Treated With Anthracyclines. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2025,14(11).
  • http://jaha.ahajournals.org
  • The publisher for Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease is Wiley.

Read more